From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Other namesYM-992; YM-35995
Routes of
ATC code
  • None
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass251.296 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Lubazodone (developmental code names YM-992, YM-35995) is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed.[1][2][3] It acts as a serotonin reuptake inhibitor (Ki for SERT = 21 nM) and 5-HT2A receptor antagonist (Ki = 86 nM), and hence has the profile of a serotonin antagonist and reuptake inhibitor (SARI).[1][2] The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the α1-adrenergic receptor (Ki = 200 nM) and the 5-HT2C receptor (Ki = 680 nM).[1] Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI.[1][2] It reached phase II clinical trials for depression,[3] but development was discontinued in 2001 reportedly due to the "erosion of the SSRI market in the United States".[1]


  1. ^ a b c d e Moltzen EK, Bang-Andersen B (2006). "Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey". Curr Top Med Chem. 6 (17): 1801–23. doi:10.2174/156802606778249810. PMID 17017959.
  2. ^ a b c Zoran Rankovic; Richard Hargreaves; Matilda Bingham (8 October 2012). Drug Discovery for Psychiatric Disorders. Royal Society of Chemistry. pp. 193–. ISBN 978-1-84973-494-3.
  3. ^ a b

External links[edit]